Long noncoding RNA ANRIL as a novel biomarker of lymph node metastasis and prognosis in human cancer: a meta-analysis

Han Wang, Yang Liu, Jianhua Zhong, Chenglong Wu, Yuantang Zhong, Gang Yang, Jinghua Zhang and Aifa Tang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:14608-14618. https://doi.org/10.18632/oncotarget.21825

Metrics: PDF 1187 views  |   HTML 2148 views  |   ?  


Han Wang1,*, Yang Liu2,*, Jianhua Zhong1, Chenglong Wu1, Yuantang Zhong2, Gang Yang2, Jinghua Zhang2 and Aifa Tang1

1Department of Urinary Surgery, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China

2Guangzhou Medical University, Guangzhou, Guangdong, China

*These authors contributed equally to this work

Correspondence to:

Aifa Tang, email: [email protected]

Keywords: ANRIL; lncRNA; cancers; lymph node metastasis; overall survival

Received: August 05, 2017     Accepted: September 22, 2017     Epub: October 11, 2017     Published: March 06, 2018


Dysregulation of the long noncoding RNA antisense noncoding RNA in the INK4 locus (ANRIL) has been reported in various solid tumors. We performed a synthetic analysis to clarify the clinical value of ANRIL as a prognostic indicator in malignant tumors. Article collection was conducted using several electronic databases, including PubMed, Web of Science, Medline, OVID and Embase (up to July 14 2017). Thirteen original studies and 1172 total patients were included in the meta-analysis. There was a significant positive association between the high expression level of ANRIL and lymph node metastasis (OR = 4.77, 95% CI: 2.30–9.91, P < 0.001) by a random effects model (I2 = 73.2, P = 0.001) and negative association with poor grade cancer (OR = 3.44, 95% CI: 1.68–7.08) by a random-effects model (I2 = 77.9, P = 0.000). The results of the meta-analysis showed that overexpression of ANRIL is positively related to poor overall survival (OS) (pooled HR = 2.12, 95% CI: 1.78–2.53, P < 0.0001) by a fixed-effects model (I2 = 0%, P = 0.654) and poor disease-free survival (DFS) (HR = 2.10, 95% CI: 1.51–2.92, P < 0.001) by a fixed-effects model (I2 = 13.3%, P = 0.315) in human solid cancers. Statistically significant associations were also found with cancer type, analysis method, sample size, and follow-up time. In conclusion, ANRIL may serve as a novel biomarker for indicating lymph node metastasis and prognosis in human cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21825